Qualigen Therapeutics (AIXC) & The Competition Critical Review

Qualigen Therapeutics (NASDAQ:AIXC) is one of 458 public companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its peers? We will compare Qualigen Therapeutics to similar companies based on the strength of its valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Earnings & Valuation

This table compares Qualigen Therapeutics and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Qualigen Therapeutics	N/A	-$6.26 million	-0.17
Qualigen Therapeutics Competitors	$432.12 million	-$67.78 million	-10.63

Qualigen Therapeutics’ peers have higher revenue, but lower earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Qualigen Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-52.57%
Qualigen Therapeutics Competitors	-2,662.14%	-363.93%	-42.95%

Volatility & Risk

Qualigen Therapeutics has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics’ peers have a beta of 5.43, suggesting that their average stock price is 443% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Qualigen Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1	0	0	0	1.00
Qualigen Therapeutics Competitors	4898	9967	15990	376	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 65.72%. Given Qualigen Therapeutics’ peers stronger consensus rating and higher probable upside, analysts plainly believe Qualigen Therapeutics has less favorable growth aspects than its peers.

Insider & Institutional Ownership

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 13.9% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Qualigen Therapeutics peers beat Qualigen Therapeutics on 9 of the 13 factors compared.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.